Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 257-263

  Torrero, Marina N ^a   Henk, William G ^a   Li, Shulin ^a,b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG POTENTIATION; ELECTROPORATION; FEMALE; GENE THERAPY; INTERFERON PRODUCTION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPORATION; FEMALE; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 31544442212     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1514     Document Type: Article

References (42)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Silverberg E, Lubera JA. Cancer statistics, 1989. CA Cancer J Clin 1989;39:3-20.
3. Liu T, Mokuolu AO, Rao CV, Reddy BS, Holt PR. Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology 1995;109:1167-72.
4. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987;78:1319-21.
5. Poddevin B, Orlowski S, Belehradek J, Jr., Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991;42:S67-75.
6. Mir LM, Orlowski S, Belehradek J, Jr., Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991;27:68-72.
7. Burger RM, Projan SJ, Horwitz SB, Peisach J. The DNA cleavage mechanism of iron-bleomycin. Kinetic resolution of strand scission from base propenal release. J Biol Chem 1986;261:15955-9.
8. Radtke K, Lornitzo FA, Byrnes RW, Antholine WE, Petering DH. Iron requirement for cellular DNA damage and growth inhibition by hydrogen peroxide and bleomycin. Biochem J 1994;302:655-64.
9. Orlowski S, An D, Belehradek J, Jr., Mir LM. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. Anticancer Drugs 1998;9:551-6.
10. Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res 1998;89:328-33.
11. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer 1999;79:1386-91.
12. Hyacinthe M, Jaroszeski MJ, Dang VV, et al. Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer 1999;85:409-17.
13. Horiuchi A, Nikaido T, Mitsushita J, Toki T, Konishi I, Fujii S. Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer 2000;88:640-4.
14. Jaroszeski MJ, Gilbert RA, Heller R. In vivo antitumor effects of electrochemotherapy in a hepatoma model. Biochim Biophys Acta 1997;1334:15-8.
15. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001;111:52-6.
16. Domenge C, Orlowski S, Luboinski B, et al. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 1996;77:956-63.
17. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994;180:211-22.
18. Bloom ET, Horvath JA. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. Implications for the age-related decline in CTL. J Immunol 1994;152:4242-54.
19. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
20. Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998;4:1183-91.
21. Han SS, Chung ST, Robertson DA, Chelvarajan RL, Bondada S. CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1. Int Immunol 1999;11:871-9.
22. Yamashita YI, Shimada M, Hasegawa H, et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001;61:1005-12.
23. Lohr F, Lo DY, Zaharoff DA, et al. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 2001;61:3281-4.
24. Suehiro T, Terashi T, Shiotani S, Soejima Y, Sugimachi K. Liver transplantation for hepatocellular carcinoma. Surgery 2002;131:S190-4.
25. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002;5:668-75.
26. Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM. Stat1-dependent, p53-independent expression of p21 (waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol 2002;22:1981-92.
27. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
28. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93.
29. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-5.
30. O'Malley BW, Jr., Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4.
31. Kishida T, Asada H, Satoh E, et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 2001;8:1234-40.
32. Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999;163:4109-13.
33. Coleman M, Muller S, Quezada A, et al. Nonviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998;9:2223-30.
34. Amerongen GPV, van Hinsbergh VWM. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vascul Pharmacol 2002;39:257-72.
35. Grimwade JE, Beerman TA. Measurement of bleomycin, neocarzinostatin, and auromomycin cleavage of cell-free and intracellular simian virus 40 DNA and chromatin. Mol Pharmacol 1986;30:358-63.
36. Beerman TA, Gutai MW. DNA damage in neocarzinostatin-, macromomycin-, and bleomycin-treated SV40 virions. Mol Pharmacol 1980;17:388-94.
37. Cullinan EB, Gawron LS, Rustum YM, Beerman TA. Extrachromosomal chromatin: novel target for bleomycin cleavage in cells and solid tumors. Biochemistry 1991;30:3055-61.
38. Lok SS, Haider Y, Howell D, Stewart JP, Hasleton PS, Egan JJ. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J 2002;20:1228-32.
39. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311.
40. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
41. Kishida T, Asada H, Itokawa Y, et al. Electrochemogene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003;8:738-45.
42. Mir LM, Orlowski S, Poddevin B, Belehradek J, Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur Cytokine Netw 1992;3:331-4.